KRAS-G12D activation and STK11 deletion are associated with…
KRAS-G12D activation and STK11 deletion are associated with human lung cancer. By developing a genetically engineered mouse model for lung tumors, you would like to know if oncogenic KRAS is required for tumor maintenance in advanced lung cancer. KRAS-G12D and STK11 mutations in Sftpc-positive lung epithelial cells are well tolerated and develop tumors when expressed in adult lungs, but cause lung failure if expressed from the embryonic stage. The following mice are available in the scientific community. (a, b, c, d, e, f, g alphabets represent strain names below) a) LSL-KRAS-G12D b) TetO- KRAS-G12D c) STK11 Lox/Lox d) Sftpc-Cre e) Sftpc-CreER f) LSL-rtTA g) LSL-RFP Which genotype and strategy is most appropriate?